Amedeo Smart

Free Medical Literature Service

 

Amedeo

Dermatology
  Free Subscription

Articles published in
Lancet
    November 2025
  1. GUTTMAN-YASSKY E, Kabashima K, Worm M, Luna PC, et al
    Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.
    Lancet. 2025 Nov 25:S0140-6736(25)01865-3. doi: 10.1016/S0140-6736(25)01865.
    >> Share

  2. ATASH K, Boesjes CM, de Bruin-Weller MS
    Targeting OX40: rocatinlimab-a novel therapy for atopic dermatitis.
    Lancet. 2025 Nov 25:S0140-6736(25)02152-X. doi: 10.1016/S0140-6736(25)02152.
    >> Share

    October 2025
  3. CACOUB P, Vieira M, Langford CA, Tazi Mezalek Z, et al
    Large-vessel vasculitis.
    Lancet. 2025;406:2017-2032.
    >> Share

  4. ALLEMANI C, Minicozzi P, Morawski B, Lima CA, et al
    Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39
    Lancet. 2025 Oct 22:S0140-6736(25)01383-2. doi: 10.1016/S0140-6736(25)01383.
    >> Share

    September 2025
  5. GOLD LS, Armstrong AW, Bissonnette R, Magnolo N, et al
    Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
    Lancet. 2025 Sep 18:S0140-6736(25)01576-4. doi: 10.1016/S0140-6736(25)01576.
    >> Share

  6. PUIG L
    Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy.
    Lancet. 2025 Sep 18:S0140-6736(25)01675-7. doi: 10.1016/S0140-6736(25)01675.
    >> Share

    August 2025

  7. Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
    Lancet. 2025;406:603-614.
    >> Share

  8. BRAIN E, Mir O, Bourbouloux E, Rigal O, et al
    Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
    Lancet. 2025;406:489-500.
    >> Share

    July 2025
  9. TANG JY, Marinkovich MP, Wiss K, McCarthy D, et al
    Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.
    Lancet. 2025;406:163-173.
    >> Share

    June 2025
  10. EBENS CL
    Targeting challenging RDEB skin wounds with gene therapy.
    Lancet. 2025 Jun 23:S0140-6736(25)01154-7. doi: 10.1016/S0140-6736(25)01154.
    >> Share

    May 2025
  11. GILBERT FJ, Payne NR, Allajbeu I, Yit L, et al
    Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial.
    Lancet. 2025 May 21:S0140-6736(25)00582-3. doi: 10.1016/S0140-6736(25)00582.
    >> Share

  12. GIMENEZ-ARNAU AM, Pinter A, Sondermann W, Reguiai Z, et al
    Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
    Lancet. 2025;405:1676-1688.
    >> Share

    February 2025
  13. GUTTMAN-YASSKY E, Renert-Yuval Y, Brunner PM
    Atopic dermatitis.
    Lancet. 2025;405:583-596.
    >> Share

  14. DUNN JA, Donnelly P, Elbeltagi N, Marshall A, et al
    Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2025;405:396-407.
    >> Share

  15. SABAT R, Alavi A, Wolk K, Wortsman X, et al
    Hidradenitis suppurativa.
    Lancet. 2025;405:420-438.
    >> Share

    January 2025
  16. FIORENTINO D, Mangold AR, Werth VP, Christopher-Stine L, et al
    Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2025;405:137-146.
    >> Share

    December 2024
  17. WEIDINGER S, Novak N
    Hand eczema.
    Lancet. 2024;404:2476-2486.
    >> Share

    November 2024
  18. CHONG DHY, Pasternak S, Taylor T, Armstrong S, et al
    Skin biopsy findings of dyskeratotic keratinocytes and vacuolar interface change in a patient with Still's disease.
    Lancet. 2024;404:e6.
    >> Share

  19. SOMA T, Oie Y, Takayanagi H, Matsubara S, et al
    Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
    Lancet. 2024 Nov 7:S0140-6736(24)01764-1. doi: 10.1016/S0140-6736(24)01764.
    >> Share

    October 2024
  20. JAIRATH V, Acosta Felquer ML, Jaihyun Cho R
    IL-23 inhibition for chronic inflammatory disease.
    Lancet. 2024;404:1679-1692.
    >> Share


  21. Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.
    Lancet. 2024;404:1407-1418.
    >> Share

  22. TARANTINO P, Tolaney SM
    Progress in breast cancer management.
    Lancet. 2024;404:1376-1378.
    >> Share

    September 2024
  23. NARAGHI K, Marzo-Ortega H
    Progressive cervical osteophytosis and dysphagia associated with isotretinoin treatment for rosacea.
    Lancet. 2024;404:e4.
    >> Share

    August 2024
  24. LEBWOHL MG, Thoma C, Haeufel T
    Spesolimab use in generalised pustular psoriasis flares - Authors' reply.
    Lancet. 2024;404:847-848.
    >> Share

  25. OSBORNE S, Thacker S, Kam O, Wescott R, et al
    Spesolimab use in generalised pustular psoriasis flares.
    Lancet. 2024;404:846-847.
    >> Share

  26. MANN GB, Rose AK, Zdenkowski N
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial - Authors' reply.
    Lancet. 2024;404:526.
    >> Share

  27. KUNKLER I, Cameron D, Dixon M, Williams L, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525.
    >> Share

  28. SWANICK CW, Kelly P, Dvorak T, Mamounas EP, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525-526.
    >> Share

  29. MO DC, Huang JF, Luo PH, Wang HL, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:524-525.
    >> Share

  30. RENERT-YUVAL Y, Guttman-Yassky E
    Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema.
    Lancet. 2024;404:409-411.
    >> Share

    July 2024
  31. RUGO HS, Bardia A, Tolaney S
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.
    Lancet. 2024;404:339-340.
    >> Share

  32. HARADA K, Ozaki A, Tanimoto T
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:339.
    >> Share

  33. MESSORI A
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338-339.
    >> Share

  34. GU Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338.
    >> Share

  35. ERGUN Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:337-338.
    >> Share

  36. ZUBERBIER T, Ensina LF, Gimenez-Arnau A, Grattan C, et al
    Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment.
    Lancet. 2024;404:393-404.
    >> Share

  37. BRUNNER PM
    A novel treatment approach for atopic dermatitis.
    Lancet. 2024 Jul 25:S0140-6736(24)01488-0. doi: 10.1016/S0140-6736(24)01488.
    >> Share

  38. SILVERBERG JI, Wollenberg A, Reich A, Thaci D, et al
    Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
    Lancet. 2024 Jul 24:S0140-6736(24)01203-0. doi: 10.1016/S0140-6736(24)01203.
    >> Share

  39. BISSONNETTE R, Warren RB, Pinter A, Agner T, et al
    Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
    Lancet. 2024 Jul 18:S0140-6736(24)01027-4. doi: 10.1016/S0140-6736(24)01027.
    >> Share

    June 2024
  40. DELALOGE S, Khan SA, Wesseling J, Whelan T, et al
    Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.
    Lancet. 2024;403:2734-2746.
    >> Share

  41. MOLINELLI E, Simonetti O
    Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.
    Lancet. 2024;403:2457-2459.
    >> Share

    May 2024
  42. BHUTTA MF, Leach AJ, Brennan-Jones CG
    Chronic suppurative otitis media.
    Lancet. 2024;403:2339-2348.
    >> Share

  43. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    >> Share

  44. PRASAD A
    Miriam Mutebi: transforming breast cancer care in Africa.
    Lancet. 2024;403:1975.
    >> Share

  45. COLES CE, Haviland JS, Kirby AM, Griffin C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply.
    Lancet. 2024;403:1752.
    >> Share

  46. GREGUCCI F, Ciabattoni A
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751-1752.
    >> Share

  47. MULLIEZ T, De Ridder M
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751.
    >> Share

  48. GUINOT JL, Gutierrez C, Hannoun-Levi JM
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1750-1751.
    >> Share

  49. MIZUMOTO M, Oshiro Y, Sakurai H
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749-1750.
    >> Share

  50. ZHAO D, Li Y, Qu Y, He C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749.
    >> Share

    April 2024
  51. DE SOUZA IC, Langer FW
    Post-radiation angiosarcoma of the breast in a patient with a history of invasive ductal carcinoma.
    Lancet. 2024;403:1681-1682.
    >> Share

  52. MOODLEY J, Unger-Saldana K
    The role of racial and ethnic discrimination in breast cancer disparities.
    Lancet. 2024 Apr 12:S0140-6736(24)00699-8. doi: 10.1016/S0140-6736(24)00699.
    >> Share

  53. COLES CE, Earl H, Anderson BO, Barrios CH, et al
    The Lancet Breast Cancer Commission.
    Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747.
    >> Share

  54. SAMARASEKERA U
    Charlotte Coles: collaborating to tackle breast cancer inequities.
    Lancet. 2024 Apr 12:S0140-6736(24)00752-9. doi: 10.1016/S0140-6736(24)00752.
    >> Share

  55. EARL HM
    Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
    Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
    >> Share

  56. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
    Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
    >> Share

    March 2024
  57. BRAYBROOKE J, Bradley R, Gray R, Hills R, et al
    Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
    Lancet. 2024;403:1240.
    >> Share

  58. KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D
    Benefits and risks of anthracyclines in early-stage breast cancer.
    Lancet. 2024;403:1239-1240.
    >> Share

  59. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    >> Share

  60. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    >> Share

    February 2024
  61. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
    Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
    Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016